「だいのうようせいこうかしょう」に関連した英語例文の一覧と使い方 - Weblio英語例文検索

本発明のスクリーニング方法によれば、サバイビン発現抑制剤がスクリーニングでき、癌、多発性硬化症、動脈硬化、前立腺肥大などのサバイビン発現亢進性疾患の治療薬として有用な物質をスクリーニングすることができる。例文帳に追加

By the screening method, a survivin expression suppressant can be screened, therefore, a material useful as a therapeutic agent for survivin expression diseases such as cancer, multiple sclerosis, arteriosclerosis, prostate gland hypertrophy and the like can be screened. - 特許庁

２　その有価証券発行勧誘等が次に掲げる場合に該当するものであつた有価証券（第一号に掲げる場合にあつては、第二条第三項第一号の規定により当該有価証券発行勧誘等の相手方から除かれた適格機関投資家が取得した有価証券に限る。）の有価証券交付勧誘等（既に発行された有価証券の売付けの申込み又はその買付けの申込みの勧誘及び組織再編成交付手続をいう。以下同じ。）で、適格機関投資家が適格機関投資家以外の者に対して行うもの（以下「適格機関投資家取得有価証券一般勧誘」という。）は、発行者が当該適格機関投資家取得有価証券一般勧誘に関し内閣総理大臣に届出をしているものでなければ、することができない。ただし、当該有価証券に関して開示が行われている場合及び内閣府令で定めるやむを得ない理由により行われることその他の内閣府令で定める要件を満たす場合は、この限りでない。例文帳に追加

(2) With regard to Securities for which a Solicitation for Newly Issued Securities, etc. falling under any of the following categories was made (in cases where the Solicitation for Newly Issued Securities, etc. having been made for these Securities falls under the category set forth in item (i) below, limited to Securities acquired by Qualified Institutional Investors who are excluded under the provision of Article 2(3)(i) from the number of persons to which the Solicitation for Newly Issued Securities, etc. was made), a Solicitation for Delivery of Existing Securities, etc. (meaning a solicitation of an application to sell or purchase already-issued Securities and Procedures Relating to Securities Delivery for Reorganization; the same shall apply hereinafter) which are made by a Qualified Institutional Investor to persons other than Qualified Institutional Investors (hereinafter referred to as a "General Solicitation for Securities Acquired by Qualified Institutional Investor") may not be made unless the Issuer of the Securities has made a notification of the General Solicitation for Securities Acquired by Qualified Institutional Investor to the Prime Minister; provided, however, that this shall not apply to the cases where disclosures have been made with regard to the Securities and to the cases where the General Solicitation for Securities Acquired by Qualified Institutional Investor is to be made for a compelling reason as specified by a Cabinet Office Ordinance or otherwise satisfies the requirements specified by a Cabinet Office Ordinance:  - 日本法令外国語訳データベースシステム

アシル化硝酸セルロースの製造方法は、反応溶媒中で第三級アミン等の触媒の存在下に、硝酸セルロースと酸ハロゲン化物等のアシル化剤とを反応させる反応工程と、その反応工程で得られた反応液を水と精製溶媒とにより精製を行う精製工程とよりなる。例文帳に追加

A preparation process of an acylated cellulose nitrate comprises a reaction step wherein a cellulose nitrate is allowed to react with an acylating agent such as acid halide or the like in a reaction solvent in the presence of a catalyst such as a tertiary amine or the like and a purification process wherein the reaction solution obtained in the reaction process is purified with water and a purification solvent. - 特許庁

器官移植、狼瘡、多発性硬化症、慢性関節リウマチ、乾癬、タイプＩ糖尿病および糖尿病による合併症、癌、ぜん息、アトピー性皮膚炎、自己免疫甲状腺疾患、潰瘍性大腸炎、クローン病、アルツハイマー病、白血病およびその他の自己免疫疾患についての免疫抑制剤を提供することを課題とする。例文帳に追加

To provide an immunosuppressive agents for organ transplants, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other indications where immunosuppression would be desirable. - 特許庁

器官移植、狼瘡、多発性硬化症、慢性関節リウマチ、乾癬、タイプＩ糖尿病および糖尿病による合併症、癌、ぜん息、アトピー性皮膚炎、自己免疫甲状腺疾患、潰瘍性大腸炎、クローン病、アルツハイマー病、白血病およびその他の自己免疫疾患についての免疫抑制剤を提供することを課題とする。例文帳に追加

To provide immunosuppressive agents for treating or preventing a disorder or condition selected from organ transplant rejection, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia, and other autoimmune diseases. - 特許庁

筋ジストロフィー、筋萎縮症、心筋梗塞、脳卒中、アルツハイマー病、頭部外傷時の意識障害や運動障害、多発性硬化症、末梢神経のニューロパシー、炎症、アレルギー、劇症肝炎、高カルシウム血症、乳癌、前立腺癌、前立腺肥大、骨粗鬆症などの治療薬として有用なカルパイン阻害活性を有する化合物を提供することである。例文帳に追加

To obtain a compound having a calpain inhibitory activity and useful as a therapeutic agent for muscular dystrophy, amyotrophy, cardiac infarction, cerebral apoplexy, Alzheimer's disease, disturbance of consciousness or dyskinesia during head trauma, multiple sclerosis, neuropathy of peripheral nerve, inflammations, allergies, fulminant hapatitis, hypercalcemia, mammary cancer, prostatic cancer, prostatomegaly, osteoporosis or the like. - 特許庁

保健・教育分野においては、特にMDGsの達成が危ぶまれていることから、人的開発の分野を中心に経常的費用についても援助を拡大すべきではないかとの議論がなされています。ただし、この点については、被援助国政府の歳入増大に対するインセンティブを阻害しないか、将来、途上国自身が経常費用を賄えるような財政構造を実現するような長期的な計画を有しているかどうかといった観点から、慎重に検討する必要があります。例文帳に追加

Progress toward the MDGs is particularly at risk in the area of human development such as health and education.Thus, it has been argued that more aid should be extended to cover recurrent costs in this area.However, this opinion must be carefully examined in the context of whether the aid might not hamper the incentive for recipient countries to increase their fiscal revenues, or whether they have a long-term plan to achieve a fiscal structure that will allow them to cover their own recurrent costs.  - 財務省

3. 前項に規定する金銭の分配のほか、無限責任組合員は、あるポートフォリオ投資に係る投資証券等（投資証券等に係る処分等、現物配当、株式分割等により本組合が取得したもののうち金銭以外のものを含む。）を現物で分配することが当該ポートフォリオ投資に関し出資をした組合員の利益に適うと合理的に判断する場合（かかる判断がなされた日を「現物分配基準日」という。）、当該ポートフォリオ投資に係る対象組合員等に対し、現物分配基準日後速やかに、当該投資証券等の分配時評価額の総額から、分配に要する諸費用（もしあれば）及び公租公課（もしあれば）の合計額を控除した上、本条第4 項に従い成功報酬（もしあれば）の額（成功報酬を投資証券等の現物で支払う場合には、当該投資証券等の分配時評価額の総額）を控除した残額に相当する当該投資証券等を、第30 条により認められる範囲において、対象持分割合（但し、脱退組合員については当該脱退組合員の脱退当時を基準とする。）に応じ按分をした割合により、それぞれ現物により分配するとができるものとする。無限責任組合員は、分配に要する諸費用及び公租公課並びに成功報酬の支払いにあてるため、分配される投資証券の一部を売却することができるものとし、かかる場合、当該売却に係る投資証券等を控除した後の当該投資証券等を対象組合員等に対し分配するものとする。当該投資証券等が市場性のある有価証券ではない場合、無限責任組合員は、(ⅰ)現物分配を行う旨及びその理由、(ⅱ)現物分配する投資証券等の明細、(ⅲ)その現物分配基準日における分配時評価額の案、並びに(ⅳ)その他その適否を判断する上で必要な事項を記載した書面を送付した上、当該ポートフォリオ投資に関し出資をした有限責任組合員の対象持割合の合計の［ ］分の［ ］以上に相当する持分を有する有限責任組合員の承認を取得しなければならないものとする。なお、第49 条第1 項は、本項の規定に基づき無限責任組合員が行う分配に準用する。例文帳に追加

(3) In addition to distribution of funds prescribed in the preceding paragraph, if the General Partner reasonably determines that it is beneficial for the Partners who have made contributions with respect to a Portfolio Investment to receive an in kind distribution of Portfolio Securities in respect of such Portfolio Investment (including non-money consideration acquired by the Partnership from a Disposition of, in kind dividends with respect to or share splits of Portfolio Securities) (the day of such determination being referred to as the “Reference Date”), the General Partner may, promptly after the Reference Date, distribute in kind to the Participating Interested Partners in respect of such Portfolio Investment their respective pro rata shares of the Portfolio Securities equivalent to the balance of the total amount of the Value at the Time of Distribution of the Portfolio Securities after the deduction of (x) the totalamount of costs and expenses, if any, and taxes and other public duties, if any, required for the distribution and (y) the amount of any incentive fee, if any, pursuant to paragraph (4) of this Article (in the case where such incentive fee is paid in kind by the Portfolio Securities, the total amount of the Value at the Time of Distribution of such Portfolio Securities), in proportion to their respective Percentage Interests (provided that, for a Withdrawing Partner, the distribution shall be based on its Percentage Interest at the time of its withdrawal), to the extent allowed by Article 30. The General Partner may sell a portion of the Portfolio Securities that are to be distributed in order to pay costs, expenses, taxes and other public duties required for such distribution and to pay such incentive fee. In such case, the General Partner shall distribute the Portfolio Securities remaining after deducting the Portfolio Securities so sold or to be so sold. If the Portfolio Securities are not Marketable Securities, the General Partner shall send a document stating (i) the proposed in kind distribution and the reason therefor, (ii) a statement of Portfolio Securities to be distributed in kind, (iii) an assessment of the Value at the Time of Distribution as of the Reference Date and (iv) other matters as required for determination of appropriateness of the proposed distribution in kind, and shall be required to obtain an approval of the Limited Partners holding interests equal to [ ]% or more of the total Percentage Interests of the Limited Partners who have made contributions to the Portfolio Investment. Article 49(1) shall apply mutatis mutandis to distribution by the General Partner pursuant to this paragraph.  - 経済産業省

3. 前項に規定する金銭の分配のほか、無限責任組合員は、投資証券等（投資証券等に係る処分等、現物配当、株式分割等により本組合が取得したもののうち金銭以外のものを含む。）を現物で分配することが組合員の利益に適うと合理的に判断する場合（かかる判断がなされた日を「現物分配基準日」という。）、組合員及び脱退組合員に対し、現物分配基準日後速やかに、当該投資証券等の分配時評価額の総額から、分配に要する諸費用（もしあれば）及び公租公課（もしあれば）の合計額を控除した上、本条第4 項に従い成功報酬（もしあれば）の額（成功報酬を投資証券等の現物で支払う場合には、当該投資証券等の分配時評価額の総額）を控除した残額に相当する当該投資証券等を、第30 条により認められる範囲において、組合員についてはその持分金額、脱退組合員については当該脱退組合員の脱退当時の持分金額の各金額に応じ按分をした上、それぞれ現物により分配することができるものとする。無限責任組合員は、分配に要する諸費用及び公租公課並びに成功報酬の支払いにあてるため、分配される投資証券等の一部を売却することができるものとし、かかる場合、当該売却に係る投資証券等を控除した後の当該投資証券等を組合員及び脱退組合員に対し分配するものとする。当該投資証券等が市場性のある有価証券ではない場合、無限責任組合員は、(ⅰ)現物分配を行う旨及びその理由、(ⅱ)現物分配する投資証券等の明細、(ⅲ)その現物分配基準日における分配時評価額の案、並びに(ⅳ)その他その適否を判断する上で必要な事項を記載した書面を送付した上、総有限責任組合員の出資口数の合計の［ ］分の［ ］以上に相当する出資口数を有する有限責任組合員の承認を取得しなければならないものとする。なお、第49 条第1 項は、本項に基づき無限責任組合員が行う分配に準用する。例文帳に追加

(3) In addition to distribution of funds prescribed in the preceding paragraph, if the General Partner reasonably determines that it is beneficial for the Partners to receive an in kind distribution of Portfolio Securities (including non-money consideration acquired by the Partnership from the Disposition of Portfolio Securities, in kind dividends or share splits) (the day of such determination being referred to as the “Reference Date”), the General Partner may, promptly after the Reference Date, distribute in kind to the Partners and any Withdrawing Partners their respective pro rata shares of the Portfolio Securities equivalent to the balance of the total amount of Value at the Time of Distribution of the Portfolio Securities after the deduction of (x) the total amount of costs and expenses, if any, and taxes and other public duties, if any, required for the distribution and (y) the amount of any incentive fee, if any, pursuant to paragraph (4) of this Article (which is, in the case where such incentive fee is paid in kind by the Portfolio Securities, the total amount of the Value at the Time of Distribution of such Portfolio Securities), in proportion to (a) in the case of a Partner, their respective Interest Amount or (b) in the case of a Withdrawing Partner, their respective Interest Amount at the time of the withdrawal of such Withdrawing Partner, to the extent allowed by Article 30. The General Partner may sell a portion of the Portfolio Securities that are to be distributed in order to pay costs, expenses, taxes and other public duties required for such distribution and to pay such incentive fee. In such case, the General Partner shall distribute to the Partners and any Withdrawing Partners the Portfolio Securities remaining after deducting the Portfolio Securities so sold or to be so sold. If the Portfolio Securities are not Marketable Securities, the General Partner shall send a document stating (i) the proposed in kind distribution and the reason therefor, (ii) a statement of Portfolio Securities to be distributed in kind, (iii) an assessment of the Value at the Time of Distribution as of the Reference Date and(iv) other matters as required to determine the appropriateness of the proposed distribution in kind, and shall be required to obtain an approval of the Limited Partners holding a Number of Partnership Units equal to [ ]% or more of the aggregate Number of Partnership Units of all of the Limited Partners. Article 49(1) shall apply mutatis mutandis to distribution by the General Partner pursuant to this paragraph.  - 経済産業省